Competing interests {28}
RS, 731875
TR has received grant support from AbbVie, Boehringer Ingelheim, Gilead Sciences, Gore, Intercept Pharmaceuticals, MSD, MYR Pharmaceuticals, Philips Healthcare, Pliant and Siemens; speaking honoraria from AbbVie, Gilead Sciences, Gore, Intercept Pharmaceuticals, MSD and Roche; consulting or advisory board fees from AbbVie, Bayer, Boehringer Ingelheim, Gilead Sciences, Intercept Pharmaceuticals, MSD and Siemens; and travel support from AbbVie, Boehringer Ingelheim, Gilead Sciences and Roche. AB has been an advisory board member for Inventiva, Bracco, General Electrics, and Boehringer Ingelheim. JT has received speaking and/or consulting fees from Versantis, Gore, Boehringer-Ingelheim, Alexion, Falk, Mallinckrodt, Grifols and CSL Behring and was supported by the German Research Foundation (DFG) project ID 403224013 – SFB 1382 (A09), by the German Federal Ministry of Education and Research (BMBF) for the DEEP-HCC project and by the Hessian Ministry of Higher Education, Research and the Arts (HMWK) for the ENABLE and ACLF-I cluster projects. The MICROB-PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875) and IHMCSA (project ID 964590) projects have received funding from the European Union’s Horizon 2020 research and innovation programme. JE, IG, RS and AT are employees of Boehringer Ingelheim. The manuscript reflects only the authors’ views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on the study design, data collection and analysis, decision to publish, or preparation of the manuscript.